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M a n u s c r i p t 2
Condensation:
There is large variations in outcomes reporting in clinical studies on pregnant women with epilepsy; there is need to identify a set of core outcome to harmonise reporting in future clinical studies.
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Abstract:
Studies on pregnant women with epilepsy should evaluate both neurological and pregnancy outcomes. We undertook a systematic review of the literature of studies on pregnant women with epilepsy to collate the outcomes reported, and the quality of outcomes report in these studies.
We searched major electronic databases (from 1999 until January 2015). Two independent reviewers selected studies and extracted data on study design, the risk of bias of the studies, journal impact factor and the quality of reported outcomes. We assessed the quality outcomes report using a six items standardised tool (score range 0-6).
There were 70 different outcomes reported in 232 studies (maternal neurological (13/70, 19%), fetal and neonatal (28/70, 40%), and obstetric outcomes (29/70, 41%)). Most studies reported on major congenital fetal abnormalities (103/232, 44%), followed by live birth (60/232, 26%). Quality of the reported outcomes was poor (mean 1·54, SD 1·36). It was associated with journal impact factor (p=0·007), but not with study design (p=0·60), or risk of bias (p=0·17).
The outcomes reported in studies on pregnant women with epilepsy varied widely, and the quality of the outcomes report was poor. There is a need to identify a set of core outcome to
Introduction
Epilepsy in pregnancy is one of the major contributory factors to maternal morbidity and mortality.(1,2) About a third of women with epilepsy experience seizure deterioration in pregnancy. (3) Often they are exposed to anti-epileptic drugs (AED) before and during pregnancy. Both uncontrolled seizures, and exposure to AEDs contribute to maternal complications (4), and adverse offspring outcomes. (5) Existing studies on epilepsy in pregnancy tend to focus on evaluation of fetal and childhood outcomes related to AED exposure. (6) The proportion of studies that report on important and clinically relevant outcome such as seizure control in pregnancy, and obstetric complications is not known. Given the relative rarity of epilepsy as a pre-existing medical condition in pregnancy, we can ill afford heterogeneity in reported outcomes.
Standardised and consistent reporting leads to meaningful evidence synthesis. Identifying gaps in outcome reporting is crucial to adequately plan future studies.
Before standardising core outcome sets for studies on pregnant women with epilepsy, there is a need to map the various outcomes reported in primary studies. We undertook a systematic review to assess the range and the quality of the outcomes reported in clinical studies on pregnant women with epilepsy.
Material and methods:
We undertook a systematic review in line with current recommendations using a prospective protocol (7) , and reported to comply with PRISMA guidelines (Appendix 1).
Literature search:
Page 5 of 22 A c c e p t e d M a n u s c r i p t 5 We searched major electronic databases MEDLINE, Embase, CINAHL, AMED and Cochrane Library (1999-January 2015) for studies on women with epilepsy. We combined the Mesh terms for ''pregnancy'', ''anti-epileptic drugs'', and ''epilepsy'' using the Boolean operators AND or OR as appropriate (Appendix 2). There were no language restrictions. We manually searched the bibliographies of relevant articles to identify papers that were not captured by electronic searches. We contacted the authors for additional data where required.
Study selection:
Two independent reviewers (BHA and JT) selected the studies. We screened the abstracts and obtained the full copies of all relevant articles. Then, we evaluated the retrieved manuscripts in detail to identify studies that may be eligible for inclusion. Any discrepancies were resolved by discussion with a third reviewer (ST). We excluded studies on non-pregnant population, only on pharmacodynamics of AEDs, surveys, case series, case reports, and animal studies.
Quality assessment of the included studies:
Two independent reviewers (BHA and JT) assessed the risk of bias in the included studies using the Newcastle-Ottawa Scale (8) for study selection, comparability and outcome assessment. The studies were allocated stars according to the rating. A study was awarded a maximum of four stars for selection, two for comparability, and three for ascertainment of exposure. Studies were considered to have a low risk of bias if they scored 4 stars for selection, 2 stars for comparability, and 3 stars for assessment of outcomes (8) . Studies with only 1 or no stars for selection, comparability, or outcome assessment were considered to have high risk of bias. The risk of bias was considered to be medium in studies with 2 or 3 stars for selection, 2 or 1 for comparability, and 2 stars for outcome assessment. For
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We assessed the quality of the outcomes reported using a standardised six items tool.(10) One point was awarded if each of the following items were met: primary outcome stated; clearly defined primary outcome; authors stated whether there were any secondary outcomes; clearly defined secondary outcomes; authors stated the rationale for choosing the reported outcomes; methods were used to enhance the quality of outcomes measurement such as the repeating measures or training in the use of measurement tools. A maximum score of 6 could be awarded for a study. We considered a score above 4 to be of high quality, 2 to 4 as moderate quality, and less than 2 as low quality.
Data extraction and analysis:
Two independent reviewers (BHA, JT) extracted data on study design (cohort studies, case control studies, and randomised controlled trials), the outcomes reported, country of the study, type of journal (general vs. specialist), impact factor of the journal, and year of publication using pre-designed forms. Journals with an impact factor above the 95th percentile of all included studies were considered to have high impact.
We categorised the reported outcomes into three main domains: Maternal neurological, obstetric, and fetal and neonatal outcomes. We grouped similar outcomes together, and estimated the proportion of these grouped outcomes that were reported in each domain. In the maternal neurological domain, outcomes related to AED such frequency of AED use in pregnancy, AED serum levels, and AED maternal toxicity were categorised as AED related
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A c c e p t e d M a n u s c r i p t 7 outcomes; and postnatal depression and psychosis were grouped as mental health related outcomes. In the fetal and neonatal domain, outcomes such as birth weight, neonatal height, and head circumference were categorised as anthropometric outcomes; and neonatal conditions such as acute respiratory distress syndrome, hypotonia, feeding problems, and hypoglycemia as neonatal clinical complications. In the obstetric domain, pregnancy viability outcomes included live birth, miscarriage, ectopic pregnancy, and termination; pregnancy specific complications included pre eclampsia and gestational diabetes; and placenta praevia and accreta were grouped as placental abnormalities.
We estimated the rates of reporting for various outcome categories in each domain, and also for individual outcomes. Due to the variation in reported outcomes, we refrained from summarising the overall rates. We used the Mann-Whitney test to determine the significance of comparative statistics for non-parametric data. Multiple linear regression analysis was done to assess the association between the quality of outcomes' report and the journal impact factor, and the risk of bias. We did not assess publication bias, as it was not appropriate. All 
Results
From 482 potentially relevant citations, we included 232 studies in our review, Figure ( . Nine studies were excluded due to inappropriate study design (2 focus groups, 6 surveys, 1 case report) and 241 studies did not report primary data in a pregnant population.
Study characteristics and risk of bias:
M a n u s c r i p t 8 All the included studies were observational in design. Over 80% were cohort studies (218/232, 94%), of which 171(78%) were prospective and 47 (22%) were retrospective cohorts. Only six per cent (14/232) were case-control studies. The majority of the studies were conducted in mainland Europe (120/232, 52%) followed by the USA (41/232, 18%) and the UK (35/232, 15%). Countries from Asia (31/232, 13%) and South America (8/232, 3%) published the least number of studies in this field. Nine tenth of all studies (209/232, 90%)
were published in specialist journals, and only a tenth (23/232, 10%) were published in general medical journals. Less than 5% of studies (11/232) were published in journals with high impact factor.
The mean star rating for the risk of bias assessment using the Newcastle-Ottawa Scale was 4·7 (SD 2·0) out of a maximum of nine stars. Over half of the included studies had a medium risk of selection bias (131/232, 56%) and a quarter had low risk of selection bias (61/232, 26%) (Figure 2 ). The risk of comparability bias was high in half of the studies (117/232, 50%) and medium in a third (75/232, 32%) of studies. More than half of the included studies had high risk of outcome assessment bias (130/232, 56%), and a quarter had a medium risk (52/232, 22%).
Variation in the reported outcomes:
Overall, 70 different individual outcomes were reported in 232 clinical studies on pregnant women with epilepsy ( Figure 3 , Table 1 ). The studies reported 13 different categories of maternal neurological, 29 obstetric, and 28 fetal and neonatal outcomes. AED related outcomes (70/232, 30%) were the most commonly reported from maternal neurological domain, followed by seizure control in 24% of studies (55/232). About 80% of all studies reported on congenital abnormality in the baby (189/232), followed by newborn were reported in less than 5% of the all studies.
Quality of the reported outcomes:
The mean quality of the reported outcomes across all studies was 1.5 (SD 1·4). Primary outcomes were not stated in two third (148/232, 64%) of the studies, and not clearly defined There were no differences in the mean scores for outcome reporting quality for cohort and case control studies (p=0·60), and for prospective and retrospective cohort studies (p=0·24).
Multiple linear regression analysis showed a significant association between the outcome reporting quality and the impact factor of the journal (β= 0.037, SE= 0.014, p= 0.007). There was no association between the quality of the studies and the outcome reporting quality (β= -0.059, SE= 0.043, p= 0.17).
Comments:
Studies on pregnant women with epilepsy have not employed randomisation, have a high risk of bias, and vary widely in the reporting of outcomes. They focus on fetal and neonatal outcomes, particularly on congenital abnormalities and viability of pregnancy, with less focus on other clinical outcomes.
Our review is the first to look at the outcomes reported in clinical studies on pregnant women with epilepsy. We used a structured comprehensive search strategy with no language restrictions. Although we aimed to capture all relevant outcomes, it is possible that studies in non-Medline indexed journals may have not been captured. We assessed the methodological quality of all included studies, and used a well-defined standardised tool to evaluate the quality of the outcomes reported (10). We categorised outcomes into three relevant domains and estimated the frequency of grouped and individual outcomes.
Assessment of risk related to congenital abnormalities appears to be the main focus in most studies. Given the significance of this finding, relative ease of obtaining relevant data, and growing evidence on association of AED and epilepsy, and congenital abnormalities, most studies have reported this finding. National and international registries appear to be the main Identifying a set of core outcomes for assessment in studies on pregnant women with epilepsy will allow studies to focus on those outcomes that are considered to be clinically relevant to both healthcare professionals and patients. Furthermore, it will facilitate robust evidence synthesis for key outcomes. Any effort to generate a set of core outcomes for clinical trials on pregnant women with epilepsy requires a consensus between different stakeholders involved in the management of epilepsy in pregnancy such as obstetricians, specialist midwives, neurologists, epilepsy nurses, neonatologists, and patient representatives. This will provide M a n u s c r i p t 12 guidance for future researchers to evaluate outcomes that are relevant to clinical practice, but less reported in the literature. Internationally the COMET (12) and The CROWN (13) initiatives have reemphasised the importance of developing core outcome sets for clinical studies. Such endeavour requires active engagement between healthcare professionals, researchers, policy makers, and patients using a robust consensus methodology. (13) Our work has highlighted the wide variation in outcomes that are currently reported, and their poor quality in clinical studies on pregnant women with epilepsy. Development of a core outcome set to be minimally reported will address the current deficiencies. M a n u s c r i p t 
